4//SEC Filing
WHITMORE R JANET 4
Accession 0000950170-24-121444
CIK 0000883107other
Filed
Nov 4, 7:00 PM ET
Accepted
Nov 5, 4:05 PM ET
Size
44.5 KB
Accession
0000950170-24-121444
Insider Transaction Report
Form 4
WHITMORE R JANET
Director
Transactions
- Purchase
Common Stock
2024-10-29$1.18/sh+2,000$2,360→ 2,009,809 total - Purchase
Common Stock
2024-10-29$0.68/sh+10,000$6,800→ 2,025,809 total - Purchase
Common Stock
2024-10-29$0.45/sh+6,667$3,000→ 2,042,476 total - Exercise/Conversion
Common Stock (Right to Buy)
2024-10-29$1.05/sh−2,000$2,100→ 0 totalExercise: $1.05From: 2017-11-17Exp: 2026-11-17→ Common Stock (2,000 underlying) - Exercise/Conversion
Common Stock (Right to Buy)
2024-10-29$0.84/sh−2,000$1,680→ 0 totalExercise: $0.84From: 2017-11-17Exp: 2026-11-17→ Common Stock (2,000 underlying) - Exercise/Conversion
Common Stock (Right to Buy)
2024-10-29$0.45/sh−6,667$3,000→ 0 totalExercise: $0.45From: 2021-06-18Exp: 2027-06-18→ Common Stock (6,667 underlying) - Exercise/Conversion
Common Stock (Right to Buy)
2024-10-29$1.17/sh−20,000$23,300→ 13,334 totalExercise: $1.17From: 2023-12-20Exp: 2029-12-20→ Common Stock (6,667 underlying) - Purchase
Common Stock
2024-10-29$0.84/sh+2,000$1,680→ 2,011,809 total - Exercise/Conversion
Common Stock (Right to Buy)
2024-10-29$0.99/sh−2,000$1,980→ 0 totalExercise: $0.99From: 2017-11-17Exp: 2026-11-17→ Common Stock (2,000 underlying) - Purchase
Common Stock
2024-10-29$0.82/sh+10,000$8,200→ 2,035,809 total - Exercise/Conversion
Common Stock (Right to Buy)
2024-10-29$1.18/sh−2,000$2,360→ 0 totalExercise: $1.18From: 2017-11-17Exp: 2026-11-17→ Common Stock (2,000 underlying) - Exercise/Conversion
Common Stock (Right to Buy)
2024-10-29$0.68/sh−10,000$6,800→ 0 totalExercise: $0.68From: 2018-02-21Exp: 2027-02-21→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock (Right to Buy)
2024-10-29$0.90/sh−2,000$1,800→ 0 totalExercise: $0.90From: 2017-11-17Exp: 2026-11-17→ Common Stock (2,000 underlying) - Exercise/Conversion
Common Stock (Right to Buy)
2024-10-29$0.82/sh−10,000$8,200→ 0 totalExercise: $0.82From: 2019-05-23Exp: 2028-05-23→ Common Stock (10,000 underlying) - Purchase
Common Stock
2024-10-29$0.90/sh+2,000$1,800→ 2,005,809 total - Exercise/Conversion
Common Stock (Right to Buy)
2024-10-29$1.10/sh−2,000$2,200→ 0 totalExercise: $1.10From: 2017-11-17Exp: 2026-11-17→ Common Stock (2,000 underlying) - Purchase
Common Stock
2024-10-29$1.05/sh+2,000$2,100→ 2,007,809 total - Purchase
Common Stock
2024-10-29$1.17/sh+6,666$7,766→ 2,049,142 total - Purchase
Common Stock
2024-10-29$1.10/sh+2,000$2,200→ 2,013,809 total - Purchase
Common Stock
2024-10-29$0.99/sh+2,000$1,980→ 2,015,809 total
Holdings
- 20,000
Common Stock (right to purchase)
Exercise: $4.17From: 2022-12-28Exp: 2028-12-28→ Common Stock (20,000 underlying) - 20,030
Deferred Common Stock
→ Common Stock (20,030 underlying) - 12,600
Common Stock (right to purchase)
Exercise: $0.61From: 2024-12-27Exp: 2030-12-27→ Common Stock (12,600 underlying) - 2,003,809
Common Stock
- 2,000
Common Stock (right to purchase)
Exercise: $1.85From: 2016-11-17Exp: 2026-11-17→ Common Stock (2,000 underlying)
Footnotes (5)
- [F1]Each share of deferred common stock represents the right to receive one share of common stock.
- [F2]The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.
- [F3]Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 20,030 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensaion Plan.
- [F4]The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. Two-thousand shares were issued with an exercise price of $0.90, 2,000 were issued with an exercise price of $1.05, 2,000 were issued with an exercise price of $1.18, 2,000 were issued with an exercise price of $0.84, 2,000 were issued with an exercise price of $1.85. 2,000 were issued with an exercise price of $1.10, and 2,000 were issued with an exercise price of $0.99.
- [F5]Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
Documents
Issuer
NANOPHASE TECHNOLOGIES Corp
CIK 0000883107
Entity typeother
Related Parties
1- filerCIK 0001173970
Filing Metadata
- Form type
- 4
- Filed
- Nov 4, 7:00 PM ET
- Accepted
- Nov 5, 4:05 PM ET
- Size
- 44.5 KB